An investigation for shareholders of GenVec, Inc. (NASDAQ:GNVC) over possible securities laws violations was announced and NASDAQ: GNVC stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 02/01/2012 -- The Shareholders Foundation announces that an investigation on behalf of investors in shares of GenVec, Inc. (NASDAQ:GNVC) was initiated over potential securities laws violations by certain officers and directors at GenVec in connection with certain statements.
Investors who purchased shares of GenVec, Inc. (NASDAQ:GNVC), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of GenVec, Inc. (NASDAQ:GNVC) concerning whether the company, certain of its officers and directors, or others have possibly violated federal securities laws. Specifically, the investigation concerns whether certain statements GenVec’s business, its prospects and its operations were potentially materially false and misleading at the time they were made.
On March 12, 2009, GenVec, Inc. (Nasdaq:GNVC) announced its financial results for the fourth quarter and year ended December 31, 2008. Among other things, GenVec, Inc said that it “announced encouraging top-line results of an interim analysis from our Phase III Pancreatic Cancer Clinical Trial (PACT). An independent Data Safety Monitoring Board reviewed the interim analysis data and recommended the trial continue as planned.”
Then on March 29, 2010, GenVec, Inc. (Nasdaq:GNVC) announced that it is discontinuing its Phase 3 clinical trial of TNFerade(TM) in patients with locally advanced pancreatic cancer based on results of an interim analysis.
GenVec, Inc said that this interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.
GenVec said that it has determined, after conferring with its independent Data Safety Monitoring Board, that the PACT trial would not meet the goal of demonstrating persuasive evidence of clinical effectiveness that could form the basis for regulatory approval in the population chosen for study.
Those who purchased shares of GenVec, Inc. (Public, NASDAQ:GNVC) and currently hold those NASDAQ:GNVC shares, may have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego